IMMUNO-ONCOLOGY INSIGHTS

Leveraging cutting edge tools to convert I-O data into knowledge

Guest Editor:
Jacques Moisan, Translational Innovation Platform - Immuno-Oncology Scientific Site Head (USA) at EMD Serono, Inc
Jacques Moisan
Translational Innovation Platform - Immuno-Oncology Scientific Site Head (USA) at EMD Serono, Inc
September 2021

  • Yes, IMMUcan! Unraveling the human tumor microenvironment

    H Hong,
    Henoch Hong
    at Merck KGaA
    R Liechti,
    Robin Liechti
    at Swiss Institute of Bioinformatics
    M Morfouace
    Marie Morfouace
    14 October 2021
    Commentary
  • Expert Roundtable: leveraging cutting edge tools to convert I-O data into knowledge

    A Sood,
    Anil K Sood
    Professor, Department of Gynecologic Oncology and Reproductive Medicine, UT MD Anderson Cancer Center
    S Prabhakaran,
    Sandhya Prabhakaran
    Applied Research Scientist, Integrated Mathematical Oncology Department, Moffitt Cancer Centre
    G Goldmacher et al.
    Gregory Goldmacher
    Executive Director, Clinical Research, Head of Clinical Imaging, Merck Research Laboratories
    Greg has been at MSD since 2015. With his team of radiologists and imaging scientists, heoversees the clinical imaging in over 200 clinical trials in oncology and other therapeutic areas.He also leads research in radiomics, artificial intelligence, novel response criteria, tumorgrowth kinetics, and other innovative approaches to clinical trial imaging. Prior to MSD, hewas a senior medical director and head of oncology imaging at a global CRO, and before thatin academia. His clinical training was in diagnostic radiology, along with a PhD and postdoctoralwork in neuroscience, and business training in finance. In his ‘free’ time, he enjoysplaying with his kids, running, and training in the martial arts.
    12 October 2021
    Expert Roundtable
  • Expert Roundtable: leveraging cutting edge tools to convert I-O data into knowledge

    A Sood,
    Anil K Sood
    Professor, Department of Gynecologic Oncology and Reproductive Medicine, UT MD Anderson Cancer Center
    S Prabhakaran,
    Sandhya Prabhakaran
    Applied Research Scientist, Integrated Mathematical Oncology Department, Moffitt Cancer Centre
    G Goldmacher et al.
    Gregory Goldmacher
    Executive Director, Clinical Research, Head of Clinical Imaging, Merck Research Laboratories
    Greg has been at MSD since 2015. With his team of radiologists and imaging scientists, heoversees the clinical imaging in over 200 clinical trials in oncology and other therapeutic areas.He also leads research in radiomics, artificial intelligence, novel response criteria, tumorgrowth kinetics, and other innovative approaches to clinical trial imaging. Prior to MSD, hewas a senior medical director and head of oncology imaging at a global CRO, and before thatin academia. His clinical training was in diagnostic radiology, along with a PhD and postdoctoralwork in neuroscience, and business training in finance. In his ‘free’ time, he enjoysplaying with his kids, running, and training in the martial arts.
    12 October 2021
    Expert Roundtable Video
  • Cancer in 4D: the importance of spatial and temporal heterogeneity through breast cancer molecular cartography

    C Martinez
    Constanza Martinez
    Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada
    11 October 2021
    Commentary
  • Cell-based therapies for cancer treatment: leveraging advanced flow cytometry for greater clinical insight

    R Fan,
    Rong Fan, PhD
    Professor of Biomedical Engineering, Yale University
    T Laskowski,
    Tamara J Laskowski, PhD
    Scientific Project Director, Adoptive Cell Therapy Platform, Dept. of Stem Cell Transplantation and Cellular Therapy MD Anderson Cancer Center
    Dr. Tamara J. Laskowski received her doctorate degree in Human Molecular Genetics and Immunology from University of Texas Health Science Center where her work focused on genome editing of patient-derived stem cells to correct genetic mutations causative of Wiskott-Aldrich Syndrome, an immunodeficiency disorder that results in severe impairments to the immune system. Subsequently, Tamara joined Dr. Laurence J.N. Cooper’s laboratory at MD Anderson Cancer Center as a fellow. Her work focused on engineering stem cells with the goal of generating off-the-shelf NK and T-cell immunotherapies for targeting solid tumor malignancies. Though Tamara remains as a collaborator in the Cooper laboratory, her work has led her to transition to Dr. James Allison’s Immunotherapy Platform at MD Anderson. In her new role as Senior Research Scientist, Dr. Laskowski’s work primarily involves immune-monitoring of patients undergoing clinical trials in Immunotherapy and development of novel immunoassays. Dr. Laskowski also shares an interest in technology innovation, and has developed multi-plex assays for testing therapies against solid tumors. In 2017, this work led to an invitation to participate in the National Science Foundation (NSF) Innovation Corps, an exclusive program through which she was trained to develop strategies for expanding the economic and societal benefits of innovative ideas which have commercialization potential. She was the sole recipient of an award for outstanding performance upon completion of the program. In addition to her research work, Dr. Laskowski participates in several educational programs at MD Anderson. She is a lecturer at MD Anderson’s School of Health Professions and also serves as a scientific communications coach teaching students and fellows how to effectively communicate science and medicine with scientific and lay audiences.
    N Senutovitch
    Nina Senutovitch, PhD
    Senior Scientist, Product Development, Cell Analytics, Sartorius
    Dr. Nina Senutovitch received her BS in Biochemistry from New Mexico State University. She completed her PhD in Biological Sciences from Carnegie Mellon University, where she developed and detailed the function of novel fluorescent probes. As a post-doctoral fellow at the University of Pittsburgh, she established biosensor-based live cell screening assays for the detection of hepatotoxicity, including the use of a human liver “organ on a chip” model. She joined Sartorius in 2019 as a Senior Scientist in Cell Analytics
    11 October 2021
    Innovator Insight
  • The use of artificial intelligence in immuno-oncology drug discovery: are we closing the gap?

    C Boutton,
    Carlo Boutton
    Author for correspondence Large Molecules Research Sanofi, Technologiepark-21, B-9052 Zwijnaarde, Belgium carlo.boutton@sanofi.com
    M Wendt
    Maria Wendt
    Large Molecules Research Sanofi, 49 New York Avenue, Framingham, MA 01701, USA
    8 October 2021
    Expert Insight
  • Overcoming purification challenges in antibody therapeutics manufacturing with subdomain-specific affinity solutions

    L Sierkstra
    Laurens Sierkstra
    Senior Director, Business Leader Purification, Thermo Fisher Scientific
    Laurens received his PhD in biotechnology in 1994 from the University of Utrecht after studying biology at the University of Leiden. He then joined Unilever as Project Manager and Unit Leader. In 2005, after the spinout of BAC BV from Unilever, he became CEO of BAC BV and set up the business in using single- domain antibodies for affinity purification, called CaptureSelect, which was sold in 2013 to Life Technologies. Since the acquisition by Thermo Fisher Scientific, he has been the business leader for the affinity purification business within the Bioproduction Division.
    8 September 2021
    Innovator Insight
  • Reaching for the stars: combining astronomy and pathology to map cancer biomarkers

    J Taube,
    Janis Taube
    Director of Dermatopathology, Johns Hopkins University and Co-Director of the Tumor Microenviornment Core, Bloomberg~Kimmel Institute of Immunotherapy and Mark Foundation Center for Advanced Imaging and Genomics
    A Szalay
    Alex Szalay
    Professor of Astronomy and Computer Science, Johns Hopkins University
    7 September 2021
    Interview
  • Gain deeper insights into the mechanisms of immune cell killing of tumor cells: accelerate your time to answer with integrated software analysis

    Gain deeper insights into the mechanisms of immune cell killing of tumor cells: accelerate your time to answer with integrated software analysis

    Dr Colby Souders
    Dr Colby Souders, Chief Scientific Officer, Abveris
    Tim Dale, PhD
    Tim Dale, PhD, Head of BioAnalytics Applications, Sartorius
    Nicola Bevan
    Nicola Bevan, Manager of Cell Imaging Applications, Sartorius
     Jeffrey Skolnik, M.D.
    Jeffrey Skolnik, M.D., Senior Vice President, Clinical Development, Inovio
    6 October 2021
    Webinar
  • Next steps in unlocking the power of computational biology for I-O target identification and validation

    N Wang
    Ning Wang
    Bioinformatics Scientist at Arcus Biosciences
    18 August 2021
    Interview
  • The therapeutic gene editing solution – cell therapy for solid tumors

    The therapeutic gene editing solution – cell therapy for solid tumors

    Barbra Sasu, PhD
    Barbra Sasu, PhD, Chief Scientific Officer, Allogene Therapeutics
    Pallavur Sivakumar, PhD
    Pallavur Sivakumar, PhD, Scientific Vice President and Head of Discovery, Immuno-Oncology and Cell Therapy Thematic Research Center, Bristol Myers Squibb
    James Trager, PhD
    James Trager, PhD, Chief Scientific Officer, Nkarta Therapeutics
    Jennifer Harbottle, PhD
    Jennifer Harbottle, PhD, Senior Scientist, R&D, Cell and Gene Therapy, Horizon Discovery
    30 September 2021
    Webinar